Imaging of Solid Tumors Using FAP-2286
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorThomas Hope
About this trial
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Eligibility criteria
Qualifiers
Age >= 18 years.
Ability to understand a written informed consent document, and the willingness to sign it.
Disqualifiers
Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
Known pregnancy.
Trial design
Treatments tested in this trial
- Gallium-68 labelled (68Ga-) FAP-2286
- Positron Emission Tomography (PET) imaging
- Copper-64 labeled (64Cu-) FAP-2286
Treatment groups
191 Participants
are divided into 4 treatment groupsSponsors and collaborators
Thomas Hope
Lead sponsor
University of California, San Francisco
Sponsor institution
Society of Abdominal Radiology
Collaborator
Source ClinicalTrials.gov